Blood parameters score predicts long-term outcomes in stage II-III gastric cancer patients

Abstract

BACKGROUNDIncreasing numbers of laboratory blood parameters (BPM) have been reported to greatly affect the long-term outcomes of gastric cancer (GC) patients. However, the existing prognostic models do not comprehensively analyze these predictors.AIMTo construct a new prognostic tool, based on all the prognostic BPM, to achieve more accurate prognosis prediction for GC.METHODSWe retrospectively assessed 850 consecutive patients who underwent curative resection for stage II-III GC from January 2010 to April 2013. The patients were classified into developing (n = 567) and validation (n = 283) cohorts using computer-generated random numbers. A scoring system, namely BPM score, was then constructed using least absolute shrinkage and selection operator (LASSO) Cox regression model in the developing cohort, and validated in the validation cohort. A nomogram consisting of BPM score and tumor-lymph node-metastasis (TNM) stage was further created. The discrimination and calibration of the nomogram were evaluated via Harrell’s C-statistic and the Hosmer-Lemeshow test.RESULTSUsing the LASSO model, we established the BPM score based on five BPM: Albumin, lymphocyte-to-monocyte ratio, neutrophil-to-lymphocyte ratio, carcinoembryonic antigen, and carbohydrate antigen 19-9. The BPM scores were divided into high- and low-BPM groups based on a cut-off value of -0.93. High-BPM patients were significantly older and had more advanced, larger tumors. In the developing cohort, significant differences were found in 5-year overall survival (OS) and 5-year disease-specific survival between the high-BPM and low-BPM patients. Similar results were found in the validation group. Multivariable analysis showed that the BPM score was an independent predictor of OS. High-BPM patients had a poorer 5-year OS for each subgroup. Furthermore, a nomogram that combined the BPM score and TNM stage had significantly better prognostic value compared with TNM stage alone.CONCLUSIONThe BPM score provides more accurate prognosis prediction in stage II-III GC patients and is an effective complement to the TNM staging system.

Serum Inflammatory Biomarkers Contribute to the Prognosis Prediction in High-Grade Glioma

“…This may result in a considerable loss of statistical power with introduction of bias in the multiple regression analysis (13). However, considering those inflammatory biomarkers as categorical variables may be more appropriate in guiding process of clinical decision-making as continuous variables could not necessarily increase the prediction performance (14). Therefore, the serum inflammatory biomarkers in our study were divided as binary variables and valued as 0 or 1 based on their optimal cut-off value instead of absolute value.…”

Systemic immune‐inflammation index has prognostic significance in pancreatic carcinoma patients: a meta-analysis

“…For example, hematological biomarkers, such as the level of lymphocytes, neutrophils, platelets, neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and C-reactive protein, are now commonly measured and applied in the assessment of systemic in ammatory response [8,9] . In fact, previous studies have con rmed that parameters are potential prognostic markers in patients with solid tumors [10][11][12][13] . Conversely, other research works have reported contradictory results on the prognostic values [14][15][16][17] .…”

Novel prognostic score based on the preoperative total bilirubin-albumin ratio and fibrinogen-albumin ratio in ampullary adenocarcinoma

“…Preoperative total bilirubin (TB) is a critical biomarker for the diagnosis of biliary obstruction and is present at the first diagnosis for the majority of AC patients. In addition, preoperative albumin has been widely used for defining immune and nutritional statuses[ 4 ]. Recently, several studies have proven that the preoperative fibrinogen-albumin ratio (FAR) is a significant prognostic biomarker in multiple tumor types, including lung cancer[ 5 ], hepatocellular carcinoma[ 6 ], colorectal cancer[ 7 ], gastric cancer[ 8 ], bladder cancer[ 9 ], and rectal cancer[ 10 ].…”